Navkar Corporation Ltd

Q1 FY22 Earnings Call Analysis

Transport Services

Full Stock Analysis
fundraise: Yescapex: Yesrevenue: Category 3margin: Category 1orderbook: No information
💰

fundraise

Any current/future new fundraising through debt or equity?

- The company has a total CAPEX plan of Rs. 135 crores for the new ICD, with around Rs. 100 crores tied up via a loan from Canara Bank; the rest is funded through cash flow. - For train replacements, an additional Rs. 150-200 crores CAPEX is planned this year, partially funded by loans. - Debt is expected to increase by approximately Rs. 50 crores this year due to these CAPEX and train replacements. - There is no explicit mention of new equity fundraising in the discussed sections. - The company aims to repay loans ahead of schedule once cash flows improve, based on past history of early repayments. - No direct comment on future equity issuance; focus is on utilizing loans and cash flows for expansion and repayments.
🏗️

capex

Any current/future capex/capital investment/strategic investment?

- Ongoing CAPEX of ₹135 crores for new ICD facility at Morbi with ~40% completion (Page 5, 9, 12). - Target to make ICD Morbi operational by Q3 FY 22-23 (around September-October 2022) (Page 5, 9,12). - Additional ₹100 crore tied up with Canara Bank for Morbi project; remaining funded via cash flow (Page 9). - Replacement of 12 leased trains with owned trains planned, improving operational efficiency and reducing costs (Page 8,14). - Total capacity post-Morbi expected to be over 1 million TEUs; phased capacity addition and incremental revenue of ₹50 crores from Morbi anticipated in first year (Page 9, 12). - Focus on strategic growth via Morbi, Vapi ICD facilities, and cross-selling to improve margins up to ~30% over 2-3 years (Page 9, 12, 14). - Further CAPEX plans depend on business growth and government policies like Gati Shakti and Dedicated Freight Corridor (Page 8,11,14).
📊

revenue

Future growth expectations in sales/revenue/volumes?

- Current utilization of 50% with a target to improve utilization by at least 10% annually. - Capacity expected to increase to around 1 million TEUs after commissioning Morbi facility. - Morbi ICD targeted to start operations by Q3 FY 22-23, with first-year revenue expected around Rs. 50 crores. - Peak revenue from Morbi projected at Rs. 400 crores within 3-4 years. - Capacity utilization growth driven by domestic, EXIM, and cross-selling business across Mumbai, Vapi, and Morbi locations. - Anticipated gradual increase in volumes aligned with government policies and easing container availability. - Replacement of lease trains with owned trains expected to improve operational efficiency and margins. - Overall target to grow EBITDA margins by approximately 20% considering new initiatives like Gati Shakti and Morbi operations.
📈

margin

Future growth expectations in earnings/operating earnings/profits/EPS?

- The company targets around 10% annual growth in capacity utilization from current ~50%. - After Morbi ICD becomes operational (targeting Q3 FY22-23), revenue is expected to increase by ₹50 crores in the first year. - Peak revenue from Morbi is projected at around ₹400 crores within 3-4 years. - Operating margin (EBITDA) targeted to improve from current ~24% to around 30% over the next 2-3 years. - Ownership of trains (replacing leased) expected to save approximately ₹2.5 crores annually and improve operational efficiency. - Benefits from government schemes (Gati Shakti, DFCC) expected to enhance profitability by 20% in a couple of years. - Diesel price hikes partly passed to customers; no major margin impact anticipated going forward. - Overall steady and gradual earnings growth is expected, with no extraordinary growth forecast but stable improvements.
📋

orderbook

Current/ Expected Orderbook/ Pending Orders?

- The transcript does not provide explicit details on the current or expected order book or pending orders in numeric terms. - However, the company is actively targeting new customers daily and expanding its operations across multiple facilities, including Mumbai, Vapi, and the upcoming Morbi ICD. - They have engaged with over 2,000 clients in Morbi across tile, paper, and chemical industries. - The company aims to grow its capacity utilization gradually by at least 10% annually. - Revenue targets include approximately Rs 50 crore additional revenue from the new Morbi ICD in the first year and a peak revenue of around Rs 400 crore over the next 3-4 years. - The management expects capacity utilization to improve post Morbi operations and the operationalization of schemes like Gati Shakti and DFCC, which will further boost business and margins.